With pressure mounting for a deficit-reduction deal in Congress, the $300 billion U.S. pharmaceutical industry is looking a little like a ship at sea with danger in the water below. Drug makers have begun to emerge as a favorite target for cost-cutting proposals from others in the healthcare sphere who hope to avoid the fiscal knife themselves, lobbyists and analysts say.
